Unibest
中EN
Sign in
← Back to patent-cliff list

Octreotide

Tier C — Watch / trade

Octreotide

Qrono Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets：SSTR

Indications (approved)：胃肠道出血, 胃肠胰神经内分泌肿瘤, Hepatocellular carcinoma, Metastatic cancer, Neuroendocrine tumour

Regional status

US
No progress
2019-09-24
EU
Phase II
2023-08-14
China
Phase III
2023-07-06
Japan
-

Synthetic routes & intermediates2 routes

Originator routes × 0Optimised (non-patent) × 2Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 3 · Total yield /
(I)120090-7-a247590-52-9(II)120090-7-a247590-53-0(IIIa)120090-7-a3228-51-1(IIIb)120090-7-a1887153-44-7(IV)120090-7-a,(IV)120090-7-b247590-54-1(V)120090-7-a83150-76-9API · Octreotide
CodeCAS No.Intermediate
(I)120090-7-a247590-52-9N-(tert-Butoxycarbonyl)-D-phenylalanyl-S-trityl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-N6-(tert-butoxycarbonyl)-L-lysyl-O-tert-butyl-L-threonyl-S-trityl-L-cysteine
(II)120090-7-a247590-53-0(4R,7S,10S,13R,16S,19R)-16-Benzyl-10-[4-[(tert-butoxycarbonyl)amino]butyl]-19-[[N-(tert-butoxycarbonyl)-D-phenylalanyl]amino]-7-[(1R)-1-tert-butoxyethyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxylic acid
(IIIa)120090-7-a3228-51-1(2R,3R)-2-Aminobutane-1,3-diol
(IIIb)120090-7-a1887153-44-7(2R,3R)-2-Aminobutane-1,3-diol 1H-benzotriazol-1-ol
(IV)120090-7-a,(IV)120090-7-b247590-54-1N-[(4R,7S,10S,13R,16S,19R)-16-Benzyl-10-[4-[(tert-butoxycarbonyl)amino]butyl]-7-[(1R)-1-tert-butoxyethyl]-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]-Nalpha-(tert-butoxycarbonyl)-D-phenylalaninamide
(V)120090-7-a83150-76-9-
OptimisedRoute 2Steps 1 · Total yield /
(IV)120090-7-a,(IV)120090-7-b247590-54-1(VI)120090-7-b247590-55-2API · Octreotide
CodeCAS No.Intermediate
(IV)120090-7-a,(IV)120090-7-b247590-54-1N-[(4R,7S,10S,13R,16S,19R)-16-Benzyl-10-[4-[(tert-butoxycarbonyl)amino]butyl]-7-[(1R)-1-tert-butoxyethyl]-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]-Nalpha-(tert-butoxycarbonyl)-D-phenylalaninamide
(VI)120090-7-b247590-55-2N-(tert-Butoxycarbonyl)-D-phenylalanyl-S-trityl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-N6-(tert-butoxycarbonyl)-L-lysyl-O-tert-butyl-L-threonyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-S-trityl-L-cysteinamide

Frequently asked questions

What are the approved indications of Octreotide?

Approved indications include: 胃肠道出血, 胃肠胰神经内分泌肿瘤, Hepatocellular carcinoma, Metastatic cancer, Neuroendocrine tumour.

When does the Octreotide patent expire?

No public expiry year is available for Octreotide yet; this page updates once verified.

How many synthesis routes are recorded for Octreotide?

2 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Octreotide intermediates?

All intermediates in Octreotide routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Octreotide intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-02